FDA Drug Safety Communication Issued In November 2014 About The Dual Antiplatelet Therapy (DAPT) Trial Which Was Published In The New England Journal of Medicine
SUMMARY: Plavix (clopidogrel) and Effient (prasugrel) are important antiplatelet blood-thinning medicines used to prevent heart attacks, strokes, and other clot-related diseases.
The Dual Antiplatelet Therapy (DAPT) trial was published by the New England Journal of Medicine (NEJM) on November 16, 2014 in this article, “Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents”.
That same day came this related item, “FDA Drug Safety Communication: FDA reviews long-term antiplatelet therapy as preliminary trial data shows benefits but a higher risk of non-cardiovascular death”.
We will watch for the FDA’s follow-up communication as regards this Plavix – Effient drug safety investigation and report significant developments here.[Read this article in full at original source]